TME Pharma N.V. (FRA:0N6A)

Market Cap	11.67M +29.0%
Revenue (ttm)	n/a
Net Income	-3.29M
EPS	-0.03
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	500
Open	0.0966
Previous Close	0.1092
Day's Range	0.0966 - 0.1180
52-Week Range	0.0333 - 0.1798
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About TME Pharma

TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. The company’s Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is mid-stage clinical development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, and glioblastoma. It also developing NOX-E36, which has completed Phase 1/2 clinical trial for...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1997
• Country: Netherlands
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 0N6A

Financial Performance

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 26, 2026

Data Sources Report a data error